Trial Profile

A phase 1, randomised, double-blind, placebo-controlled, study to evaluate the safety, tolerability and pharmacokinetics of MAP 315 in healthy adults

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MAP 315 (Primary)
Indications Ulcerative colitis
Focus Adverse reactions; First in man
Sponsors Microba Life Sciences

Most Recent Events

30 Jun 2023 According to a Microba media release, this trial is being conducted by Nucleus Network in Melbourne, Australia.
30 Jun 2023 New trial record
28 Jun 2023 According to a Microba media release, the first patient has been dosed in this study. Results from the trial are expected to be available in December 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com